INmune Bio gets FDA IND approval for prostate cancer immunotherapy

• The US FDA has cleared an Investigational New Drug application from INmune Bio (NASDAQ:INMB) for its castration-resistant prostate cancer immunotherapy candidate INKmune.
• INKmune is a natural killer cell immunotherapy.
• A phase 1/2 open-label trial is slated to enroll the first patients in the second half of the year.
• INKmune is already in phase 1 testing for myelodysplastic syndrome or acute myeloid leukemia.

 More on INmune Bio

• INmune Bio: INKmune For Solid Tumors And Other Potential Catalysts

• INmune Bio: Alzheimer's Disease Treatment Lottery Ticket